Novel mouse model reveals the mechanisms of a rare genetic encephalopathy

A groundbreaking study published in the journal Brain has unveiled key insights into a rare and severe genetic encephalopathy, offering researchers a powerful new tool to investigate its underlying causes and explore potential treatments. The research, led by Dr. Alexey Pshezhetsky and Dr. Elsa Rossignol from the University of Montreal, involved the development of the first mouse model that accurately replicates the human form of the disease.

This encephalopathy, caused by a mutation in the DHDDS gene, typically manifests in early childhood through intellectual disability, epileptic seizures, involuntary movements, and coordination difficulties that worsen over time. With approximately 200 patients identified worldwide, the condition's cellular and molecular mechanisms had remained largely unknown.

The researchers used a unique mouse model to track the effects of one of the disease-causing mutations, examining its molecular consequences and neurological manifestations through a comprehensive approach involving genetics, biochemistry, proteomics, and lipidomics. The study, published in Brain, revealed how a defect in the production of molecules essential for protein glycosylation disrupts neuronal circuits in the brain, leading to a range of neurological symptoms, including seizures, movement abnormalities, and cognitive deficits.

This discovery establishes a direct link between the genetic mutation, the observed molecular abnormalities, and the resulting neurological symptoms, providing an unprecedented platform for evaluating future targeted therapies, including the repurposing of existing drugs. Notably, acetazolamide, a medication already approved for other conditions, was found to reduce susceptibility to epileptic seizures in the experimental model.

However, further studies using patient-derived neurons and clinical trials will be necessary to validate this therapeutic approach. The research marks a significant step forward in understanding the disease, improving patient care, and ultimately developing targeted treatments for young patients affected by this rare encephalopathy.